Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SenzaGen

4.66 SEK+4.25 %16/11 12:53
Less than 1K followers

SENZA

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+4.25 %
+0.87 %
-12.08 %
-14.34 %
-23.36 %
-27.19 %
-38.68 %
-62.11 %
-88.97 %

SenzaGen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.

Read more
Market cap
151.49M SEK
Turnover
243.2K SEK
Revenue
57.97M
EBIT %
-20.05 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
18/2
2027

Annual report '26

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release2026-11-05 18:35

SenzaGen slutför förvärvet av Alcyomics

SenzaGen
Press release2026-11-05 18:35

SenzaGen completes the acquisition of Alcyomics

SenzaGen
SenzaGen, Webcast, Q3'26
Webcast2026-11-05 10:00

SenzaGen, Webcast, Q3'26

SenzaGen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-11-05 07:30

SenzaGens delårsrapport januari-september 2026 | Ökade intäkter och effektivitet ger vinst i kvartalet; förvärv expanderar de kommersiella möjligheterna framåt

SenzaGen
Regulatory press release2026-11-05 07:30

SenzaGen’s interim report January–September 2026 | Increased revenue and efficiency deliver a profitable quarter; acquisition expands future commercial opportunities

SenzaGen
Press release2026-11-02 08:30

SenzaGens dotterbolag säkrar order värd 2,8 MSEK från befintlig kund

SenzaGen
Press release2026-11-02 08:30

SenzaGen subsidiary secures SEK 2.8 million order from existing customer

SenzaGen
Press release2026-10-30 08:30

Inbjudan till presentation av SenzaGens delårsrapport Q3 2026

SenzaGen
Press release2026-10-30 08:30

Invitation to the presentation of SenzaGen's Q3 2026 interim report

SenzaGen
SenzaGen, Press Conference, October 2026
Webcast2026-10-29 13:00

SenzaGen, Press Conference, October 2026

SenzaGen
Press release2026-10-28 19:42

Inbjudan till webbsänd presentation med anledning av SenzaGens förvärv av Alcyomics

SenzaGen
Press release2026-10-28 19:42

Invitation to a webcast presentation regarding SenzaGen’s acquisition of Alcyomics

SenzaGen
Regulatory press release2026-10-28 19:40

SenzaGen förvärvar Alcyomics, en ledande brittisk aktör inom djurfri immuntoxikologi för läkemedelsutveckling

SenzaGen
Regulatory press release2026-10-28 19:40

SenzaGen acquires Alcyomics, a leading UK-based provider of non-animal immunotoxicology solutions for drug development

SenzaGen
Regulatory press release2026-08-20 17:00

Rättelse: SenzaGens delårsrapport januari-juni 2026 Ι Fortsatt stark utveckling i Q2 2026 med 13 % tillväxt och positivt kassaflöde

SenzaGen
Regulatory press release2026-08-20 17:00

Correction: SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow

SenzaGen
SenzaGen, Webcast, Q2'26
Webcast2026-08-20 10:00

SenzaGen, Webcast, Q2'26

SenzaGen
Regulatory press release2026-08-20 07:30

SenzaGens delårsrapport januari-juni 2026 | Fortsatt stark utveckling i Q2 2026 med 13% tillväxt och positivt kassaflöde

SenzaGen
Regulatory press release2026-08-20 07:30

SenzaGen’s interim report January–June 2026 | Continued strong development in Q2 2026 – 13% growth with positive cash flow

SenzaGen
Press release2026-08-18 08:30

Invitation to the presentation of SenzaGen's January-June 2026 interim report

SenzaGen